Rena Conti
Rena Conti
Associate Professor, University of Chicago
Verified email at
Cited by
Cited by
Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States
DM Qato, GC Alexander, RM Conti, M Johnson, P Schumm, ST Lindau
Jama 300 (24), 2867-2878, 2008
Racial disparities in access to renal transplantation—clinically appropriate or due to underuse or overuse?
AM Epstein, JZ Ayanian, JH Keogh, SJ Noonan, N Armistead, PD Cleary, ...
New England Journal of Medicine 343 (21), 1537-1544, 2000
Pricing in the market for anticancer drugs
DH Howard, PB Bach, ER Berndt, RM Conti
Journal of Economic Perspectives 29 (1), 139-62, 2015
Impact of FDA black box advisory on antipsychotic medication use
ER Dorsey, A Rabbani, SA Gallagher, RM Conti, GC Alexander
Archives of internal medicine 170 (1), 96-103, 2010
Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review
SB Dusetzina, AS Higashi, ER Dorsey, R Conti, HA Huskamp, S Zhu, ...
Medical care 50 (6), 466, 2012
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists
RM Conti, AC Bernstein, VM Villaflor, RL Schilsky, MB Rosenthal, ...
Journal of Clinical Oncology 31 (9), 1134, 2013
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities
R Conti, DL Veenstra, K Armstrong, LJ Lesko, SD Grosse
Medical Decision Making 30 (3), 328-340, 2010
Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000–2010
CF Garfield, ER Dorsey, S Zhu, HA Huskamp, R Conti, SB Dusetzina, ...
Academic pediatrics 12 (2), 110-116, 2012
Overspending driven by oversized single dose vials of cancer drugs
PB Bach, RM Conti, RJ Muller, GC Schnorr, LB Saltz
Bmj 352, 2016
Mental health policy and psychotropic drugs
RG Frank, RM Conti, HH Goldman
The Milbank Quarterly 83 (2), 271-298, 2005
Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States
WV Padula, RA Larson, SB Dusetzina, JF Apperley, R Hehlmann, ...
Journal of the National Cancer Institute 108 (7), djw003, 2016
An analysis of whether higher health care spending in the United States versus Europe is ‘worth it’in the case of cancer
T Philipson, M Eber, DN Lakdawalla, M Corral, R Conti, DP Goldman
Health Affairs 31 (4), 667-675, 2012
Cost consequences of the 340B drug discount program
RM Conti, PB Bach
Jama 309 (19), 1995-1996, 2013
Making medicines affordable: a national imperative
National Academies of Sciences, Engineering, and Medicine
National Academies Press, 2018
21st century pharmacovigilance: efforts, roles, and responsibilities
PJ Pitts, H Le Louet, Y Moride, RM Conti
The Lancet Oncology 17 (11), e486-e492, 2016
Association of prescription drug price rebates in Medicare Part D with patient out-of-pocket and federal spending
SB Dusetzina, RM Conti, LY Nancy, PB Bach
JAMA internal medicine 177 (8), 1185-1188, 2017
The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities
RM Conti, PB Bach
Health Affairs 33 (10), 1786-1792, 2014
Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998–2009
J Pillarella, A Higashi, GC Alexander, R Conti
Psychiatric services 63 (1), 83-86, 2012
Racial and ethnic disparities in cardiovascular medication use among older adults in the United States
DM Qato, ST Lindau, RM Conti, LP Schumm, GC Alexander
Pharmacoepidemiology and drug safety 19 (8), 834-842, 2010
National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011
RM Conti, AJ Fein, SS Bhatta
Health Affairs 33 (10), 1721-1727, 2014
The system can't perform the operation now. Try again later.
Articles 1–20